CVS Caremark Excluded AbbVie’s Humira, Achieves $1.5B Savings Through Biosimilars
CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo to major commercial formularies starting April 1, replacing Amgen’s Prolia and Lilly’s Forteo with options over 50% cheaper per prescription. The PBM previously removed AbbVie’s Humira in favor of biosimilars, generating $1.5 billion in gross savings.
1. Formulary Expansion for Osteoporosis Biosimilars
Beginning April 1, 2026, CVS Caremark will add biosimilars Ospomyv (Cordavis) and Stoboclo (Celltrion) plus generic teriparatide drugs Bonsity and Tymlos to its national commercial template formularies, replacing branded Prolia and Forteo to deliver more than 50% lower costs per prescription.
2. Impact on AbbVie’s Humira Strategy
This move builds on CVS Caremark’s prior decision to exclude AbbVie’s Humira from its commercial formulary in favor of lower-cost biosimilars, underscoring a broader push to drive competition against high-priced originator biologics.
3. Savings and Member Transition
CVS reports that its formulary tools have helped clients and members generate $1.5 billion in gross savings; 96% of Humira users successfully transitioned to biosimilars, with dedicated support from CVS Specialty to guide prescribers and patients through the switch.